Notably, the JAK1/2 inhibitor ruxolitinib has shown efficacy in patients with CSF3R T618I‐positive CNL and anecdotal benefit in other CSF3R‐mutated myeloid neoplasms [24]. The gene discussed is CSF3R; the disease is myeloid neoplasm.